Literature DB >> 5511783

Occurrence of an abnormal lipoprotein in patients with liver disease.

A Ross, G M Murphy, P A Wilkinson, G L Mills, S Sherlock.   

Abstract

An abnormal lipoprotein, containing a high proportion of unesterified cholesterol and phospholipid, has previously been described as occurring in the serum of patients with obstructive jaundice, and has been called lipoprotein X. Using an immunoelectrophoretic method for the detection of lipoprotein X in serum, the sera of 97 patients with liver disease have been screened and the associated biochemical features measured.Lipoprotein X was found in 45% of cases of liver disease with cholestatic features, and was not detected in cases of liver disease without cholestasis. The incidence of lipoprotein X in different causes of cholestatis varied, and while it was commonest in cases of extrahepatic obstruction of recent onset, occurring in 75% of cases, it was also found in primary biliary cirrhosis in 48% of cases, and in cholestatic hepatitis, less commonly.The cause of the appearance of lipoprotein X is unknown, but analysis of associated biochemical features suggested a relationship to physical biliary obstruction rather than a derangement of liver cell function.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5511783      PMCID: PMC1553163     

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Protein-lipid relationships in human plasma: in biliary cirrhosis, obstructive jaundice, and acute hepatitis.

Authors:  H A EDER; E M RUSS; R A R PRITCHETT; M M WILBER; D P BARR
Journal:  J Clin Invest       Date:  1955-07       Impact factor: 14.808

2.  Ultracentrifugal characterization of the lipoprotein spectrum in obstructive jaundice: studies of serum lipid relationships in intra-and extrahepatic biliary obstruction.

Authors:  R H FURMAN; L L CONRAD
Journal:  J Clin Invest       Date:  1957-05       Impact factor: 14.808

3.  Lipoproteins in primary biliary cirrhosis.

Authors:  E M RUSS; J RAYMUNT; D P BARR
Journal:  J Clin Invest       Date:  1956-02       Impact factor: 14.808

4.  The relationship between serum lipids and the electrophoretic pattern, with particular reference to patients with primary biliary cirrhosis.

Authors:  H G KUNKEL; E H AHRENS
Journal:  J Clin Invest       Date:  1949-11       Impact factor: 14.808

5.  Lipoprotein patterns of serum obtained by zone electrophoresis.

Authors:  H G KUNKEL; R J SLATER
Journal:  J Clin Invest       Date:  1952-07       Impact factor: 14.808

6.  A fluorimetric and enzymatic method for the estimation of serum total bile acids.

Authors:  G M Murphy; B H Billing; D N Baron
Journal:  J Clin Pathol       Date:  1970-10       Impact factor: 3.411

7.  Plasma lipoproteins in liver disease. I. Immunologically distinct low-density lipoproteins in patients with biliary obstruction.

Authors:  S Switzer
Journal:  J Clin Invest       Date:  1967-11       Impact factor: 14.808

8.  Chronic cholangitides: aetiology, diagnosis, and treatment.

Authors:  S Sherlock
Journal:  Br Med J       Date:  1968-08-31

9.  A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects.

Authors:  D Seidel; P Alaupovic; R H Furman
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

  9 in total
  3 in total

1.  Intrahepatic cholestasis as a side-effect of drug therapy.

Authors:  G Feuer; M S Dhami
Journal:  Can Fam Physician       Date:  1982-07       Impact factor: 3.275

2.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

3.  Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Authors:  Shimpi Bedi; Erwin Garcia; Elias J Jeyarajah; Irina Shalaurova; Maria Camila Perez-Matos; Z Gordon Jiang; Robin P F Dullaart; Steven P Matyus; William J Kirk; James D Otvos; W Sean Davidson; Margery A Connelly
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.